Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Filed Chapter 11
Tricida, Inc. (TCDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/14/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Tricida, Inc. Condensed Balance Sheets"
11/08/2021 8-K Quarterly results
Docs: "Tricida, Inc. Condensed Balance Sheets"
08/09/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Tricida Announces Third Quarter 2020 Financial Results"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Tricida Announces First Quarter 2020 Financial Results Webcast Today at 4:30 pm Eastern Time"
11/14/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Tricida Announces Second Quarter 2019 Financial Results Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., August 8, 2019 — Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer , a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease , announced today financial results for the three and six months ended June 30, 2019 and provided an update on key initiatives, including its planned submission of the New Drug Application for veverimer. Tricida has narrowed the timing for i..."
05/08/2019 8-K Quarterly results
Docs: "Tricida Announces First Quarter 2019 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 8, 2019 — Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer , a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease , announced today financial results for the three months ended March 31, 2019 and provided an update on key initiatives. Recent Highlights"
11/08/2018 8-K Quarterly results
Docs: "Tricida Announces Third Quarter 2018 Financial Results Advanced Key Initiatives for NDA Submission Launched Non-Branded Metabolic Acidosis Disease Awareness Campaign Presented TRCA-301 Pivotal Trial Results at ASN Kidney Week Late-Breaker Session Webcast Today at 5:00 pm ET SOUTH SAN FRANCISCO, Calif., November 8, 2018 — Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease , announced today financial results for the three and nine months ended September 30, 2018 and provided an update on key initiatives. “We’ve made significant progress on our major initiatives supporting both our plan to submit our New Drug Ap..."
08/08/2018 8-K Quarterly results
Docs: "Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives Completed Positive Pivotal Phase 3 Trial for TRC101 Completed $255.6 Million Initial Public Offering Webcast Today at 5:00 pm ET SOUTH SAN FRANCISCO, Calif., August 8, 2018 — Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with chronic kidney disease , announced today financial results for the three and six months ended June 30, 2018 and provided an update on key initiatives. “Following the positive results of our pivotal Phase 3 trial and the successful completion of our initial public offering in which we raised gross proceeds of $255.6 million, we are now f..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy